Thalamus News and Research

RSS

The Thalamus is an area of the brain that helps process information from the senses and transmit it to other parts of the brain.

Two major classes of brain cells repress neural activity in specific mathematical ways

The brain has billions of neurons, arranged in complex circuits that allow us to perceive the world, control our movements and make decisions. Deciphering those circuits is critical to understanding how the brain works and what goes wrong in neurological disorders.

9 Aug 2012

Scientists discover important neural mechanism underlying dyslexia

To participate successfully in life, it is important to be able to read and write. Nevertheless, many children and adults have difficulties in acquiring these skills and the reason is not always obvious. They suffer from dyslexia which can have a variety of symptoms. Thanks to research carried out by Bego-a D-az and her colleagues at the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, a major step forward has been made in understanding the cause of dyslexia.

8 Aug 2012

Adult human brain remarkably malleable and capable of new feats

There is growing evidence that, beyond what was previously believed, the adult human brain is remarkably malleable and capable of new feats -- even in the last decades of life.

2 Aug 2012

MRI infant prognosis unaffected by hypothermia

Magnetic resonance imaging is prognostic for newborn infants with hypoxic-ischemic encephalopathy regardless of treatment with hypothermia, research shows.

9 Jul 2012

Genetic risk for schizophrenia linked to brain volume alterations

Patients with schizophrenia and their unaffected first-degree relatives show altered gray and white matter volumes in specific brain regions compared with mentally healthy individuals, researchers report.

26 Jun 2012

Insight linked to gray matter volume in FEP patients

Results from an Irish study show that poor insight is associated with increased gray matter volume in subcortical and frontotemporal brain regions among patients with first-episode psychosis, but not in those with chronic schizophrenia.

20 Jun 2012

New study into pain associated with diabetes

Researchers in Sheffield have been awarded over £310,000 to carry out a study that could help revolutionise the way clinicians treat the pain experienced by thousands of people with diabetes.

8 Jun 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

Brain can rewire even at an advanced age

"This study overturns decades-old beliefs that most of the brain is hard-wired before a critical period that ends when one is a young adult," said MPFI neuroscientist Marcel Oberlaender, PhD, first author on the paper.

25 May 2012

Changes in sensory experience can cause massive rewiring of the brain

Despite a long-held scientific belief that much of the wiring of the brain is fixed by the time of adolescence, a new study shows that changes in sensory experience can cause massive rewiring of the brain, even as one ages. In addition, the study found that this rewiring involves fibers that supply the primary input to the cerebral cortex, the part of the brain that is responsible for sensory perception, motor control and cognition.

25 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

Breakdown of white-matter pathways affects decision-making as we age

If you are an aging baby boomer and you've noticed it's a bit harder to drive to unfamiliar locations or to pick a new brand of olive oil at the supermarket, you can blame it on the white matter in your brain.

20 Apr 2012

Scientists image process of consciousness after general anesthesia

Awakening from anesthesia is often associated with an initial phase of delirious struggle before the full restoration of awareness and orientation to one's surroundings. Scientists now know why this may occur: primitive consciousness emerges first. Using brain imaging techniques in healthy volunteers, a team of scientists led by Adjunct Professor Harry Scheinin, M.D. from the University of Turku, Turku, Finland in collaboration with investigators from the University of California, Irvine, USA, have now imaged the process of returning consciousness after general anesthesia.

5 Apr 2012

Childhood onset temporal lobe epilepsy has a significant impact on brain aging

New research confirms that childhood onset temporal lobe epilepsy has a significant impact on brain aging. Study findings published in Epilepsia, a peer-reviewed journal of the International League Against Epilepsy (ILAE), show age-accelerated ventricular expansion outside the normal range in this patient population.

2 Apr 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

Biologists identify how and where the brain processes FM sweeps

In both animals and humans, vocal signals used for communication contain a wide array of different sounds that are determined by the vibrational frequencies of vocal cords. For example, the pitch of someone's voice, and how it changes as they are speaking, depends on a complex series of varying frequencies. Knowing how the brain sorts out these different frequencies-which are called frequency-modulated (FM) sweeps-is believed to be essential to understanding many hearing-related behaviors, like speech.

9 Mar 2012

Scientists reveal how psychostimulant drugs work to control hyperactivity

It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.

8 Feb 2012

Magic Mushroom’s compound may help in some mental disorders: Study

There has been little research on the mechanism of action of “magic mushrooms” on the brain. A growing number of studies suggested that perhaps the mushrooms' key ingredient could work magic for certain mental disorders. New research in Proceedings of the National Academy of Sciences sheds light on why one of the mushrooms' hallucinogenic chemical compounds, psilocybin, may hold promise for the treatment of depression.

24 Jan 2012